AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Ampyrone is commonly used to alleviate various types of pain, including headaches, dental pain, menstrual pain, musculoskeletal pain, and postoperative pain. It acts by inhibiting the synthesis of prostaglandins, which are chemical mediators involved in the perception of pain and inflammation.
Fever Reduction: Ampyrone is effective in reducing fever by acting on the hypothalamus, which regulates body temperature. It helps lower elevated body temperature in conditions such as infections, inflammatory disorders, and other febrile illnesses.
Inflammatory Conditions: Ampyrone possesses anti-inflammatory properties and may be used to alleviate inflammation associated with conditions such as arthritis, rheumatic disorders, gout, and soft tissue injuries. It inhibits the production of inflammatory mediators and suppresses the inflammatory response.
Smooth Muscle Spasm: Ampyrone has muscle-relaxing properties and may help alleviate smooth muscle spasms associated with conditions such as colic, renal colic, gastrointestinal spasms, and biliary colic. It acts by reducing muscle contractions and promoting muscle relaxation.
Postoperative Pain Management: Ampyrone may be used as part of multimodal analgesia for postoperative pain management following surgical procedures. It can provide effective pain relief and reduce the need for opioid analgesics, thereby minimizing opioid-related side effects and complications.
Labor Pain: Ampyrone may be administered during labor to relieve pain and discomfort. It can help reduce the intensity of uterine contractions and alleviate labor-related pain, making labor more manageable for the mother.
Migraine Management: Ampyrone is sometimes used in the treatment of migraines and severe headaches. It can help alleviate migraine-associated symptoms such as headache pain, nausea, and sensitivity to light and sound.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.4 | -0.33 |
| ADHD | 0.4 | 0.3 | 0.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.4 | 2 |
| Allergies | 0.9 | 0.6 | 0.5 |
| Allergy to milk products | 0.3 | 0.6 | -1 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.2 | 1 | 0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | |
| Ankylosing spondylitis | 1.4 | 0.6 | 1.33 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Asthma | 1.5 | 0.6 | 1.5 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 1.4 | 0.6 | 1.33 |
| Autism | 1.3 | 1.6 | -0.23 |
| Autoimmune Disease | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 1.2 | 1.2 | 0 |
| Celiac Disease | 0.3 | 1.5 | -4 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 0.6 | 1.7 | -1.83 |
| Chronic Kidney Disease | 1 | 0.4 | 1.5 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Cognitive Function | 1.2 | 0.3 | 3 |
| Colorectal Cancer | 1 | 0.6 | 0.67 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | -0.3 | |
| COVID-19 | 1.2 | 1.7 | -0.42 |
| Crohn's Disease | 1.2 | 1.5 | -0.25 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.6 | -0.6 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 1.5 | 1.5 | 0 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.3 | -0.3 | |
| Endometriosis | 1.2 | 0.3 | 3 |
| Epilepsy | 0.6 | 0.6 | 0 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 0.9 | 0.6 | 0.5 |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0.7 | 0.29 |
| gallstone disease (gsd) | 0.6 | 0.3 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.3 | 0.7 | -1.33 |
| Gout | 0.5 | 0.5 | |
| Graves' disease | 0.6 | 1.2 | -1 |
| Gulf War Syndrome | 0.3 | -0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.3 | 1 | 0.3 |
| Heart Failure | 0.3 | 0.3 | 0 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hyperglycemia | 0.6 | -0.6 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.6 | 0.7 | 1.29 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.2 | 0.3 | 3 |
| IgA nephropathy (IgAN) | 0.3 | 0.3 | 0 |
| Inflammatory Bowel Disease | 0.6 | 0.9 | -0.5 |
| Insomnia | 0.9 | 0.6 | 0.5 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 1.3 | 0.9 | 0.44 |
| ischemic stroke | 0.7 | 0.3 | 1.33 |
| Liver Cirrhosis | 1.2 | 1.2 | 0 |
| Long COVID | 0.9 | 1.6 | -0.78 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.6 | -0.6 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 1.1 | -1.1 | |
| ME/CFS without IBS | 1.7 | -1.7 | |
| Menopause | 0.1 | 0.1 | |
| Metabolic Syndrome | 1.2 | 1.6 | -0.33 |
| Mood Disorders | 0.9 | 0.9 | 0 |
| Multiple Sclerosis | 0.9 | 1.1 | -0.22 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.9 | -0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.9 | 0.33 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 2.5 | 2 | 0.25 |
| obsessive-compulsive disorder | 0.6 | 1.3 | -1.17 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 0.3 | 0.9 | -2 |
| Parkinson's Disease | 0.7 | 1.7 | -1.43 |
| Polycystic ovary syndrome | 0.6 | 0.6 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.6 | 0.6 | |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.8 | 0.3 | 1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 1.2 | 0.67 |
| Rosacea | 0.4 | 0.3 | 0.33 |
| Schizophrenia | 0.9 | 0.9 | 0 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 1.2 | -1.2 | |
| Sleep Apnea | 1.2 | 0.3 | 3 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.1 | 2 |
| Stress / posttraumatic stress disorder | 1.2 | 0.6 | 1 |
| Systemic Lupus Erythematosus | 0.3 | 0.8 | -1.67 |
| Tic Disorder | 0.9 | -0.9 | |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 0.3 | 1.3 | -3.33 |
| Type 2 Diabetes | 1.2 | 1.5 | -0.25 |
| Ulcerative colitis | 1.4 | 0.6 | 1.33 |
| Unhealthy Ageing | 1 | 0.3 | 2.33 |
| Vitiligo | 0.9 | 0.3 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
